| Human immunodeficiency virus I infection
Apretude vs Complera
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Apretude vs Complera with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsComplera has a higher rate of injection site reactions vs Apretude based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Complera but not Apretude, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Apretude
Complera
At A Glance
IM injection
Every 2 months
HIV integrase strand transfer inhibitor
Oral
Once daily
NRTI/NNRTI fixed-dose combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection 600-mg (3-mL) gluteal IM initiation injections 1 month apart for 2 consecutive months, then 600-mg (3-mL) every 2 months; optional oral lead-in with cabotegravir 30 mg once daily for at least 28 days prior to first injection.
Human immunodeficiency virus I infection One tablet orally once daily with food for adults and pediatric patients weighing at least 35 kg; not recommended in patients with estimated creatinine clearance below 50 mL/min.
Pregnancy One tablet once daily may be continued in virologically suppressed patients (HIV-1 RNA less than 50 copies/mL); monitor viral load closely due to lower rilpivirine exposures during pregnancy.
Rifabutin coadministration Add one additional 25 mg rilpivirine (Edurant) tablet once daily with a meal for the duration of rifabutin coadministration.
Contraindications
- Unknown or positive HIV-1 status
- Previous hypersensitivity reaction to cabotegravir
- Coadministration with anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin) due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
- Coadministration with antimycobacterials rifampin or rifapentine due to significant UGT1A1 induction decreasing cabotegravir plasma concentrations
- Coadministration with carbamazepine, oxcarbazepine, phenobarbital, or phenytoin
- Coadministration with rifampin or rifapentine
- Coadministration with dexamethasone (systemic, more than a single dose)
- Coadministration with St John's wort (Hypericum perforatum)
- Coadministration with proton pump inhibitors (e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole)
Adverse Reactions
Most common (>=1%) Injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back pain, upper respiratory tract infection
Serious Hypersensitivity reactions, hepatotoxicity, depressive disorders including depression, suicidal ideation, and suicide attempt
Postmarketing Hypersensitivity reactions (angioedema, urticaria), Stevens-Johnson syndrome/toxic epidermal necrolysis
Most common (>=2%) Depressive disorders, headache, insomnia, abnormal dreams, dizziness, nausea, rash
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight gain, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, allergic reaction including angioedema, lactic acidosis, pancreatitis, rhabdomyolysis, osteomalacia, acute renal failure, Fanconi syndrome
Pharmacology
Cabotegravir is an HIV integrase strand transfer inhibitor (INSTI) that inhibits HIV replication by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for the HIV replication cycle.
COMPLERA is a fixed-dose combination antiretroviral containing emtricitabine (nucleoside reverse transcriptase inhibitor), rilpivirine (non-nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor); each component inhibits HIV-1 reverse transcriptase through distinct mechanisms to suppress viral replication.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Apretude
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Complera
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Apretude
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Complera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Apretude
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Complera
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Apretude Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ApretudeView full Apretude profile
CompleraView full Complera profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.